Inflammatory Bowel Diseases

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
Importance: Proactive therapeutic drug monitoring (TDM), consisting of individualized treatment based on scheduled assessments of serum …
Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, Marthe Kirkesæther Brun, Øystein Sandanger, Kristin Hammersbøen Bjørlykke, Joseph Sexton, Inge Christoffer Olsen, Johanna Elin Gehin, David John Warren, Rolf Anton Klaasen, Geir Noraberg, Trude Jannecke Bruun, Christian Kvikne Dotterud, Maud-Kristine Aga Ljoså, Anne Julsrud Haugen, Rune Johan Njålla, Camilla Zettel, Carl Magnus Ystrøm, Yngvill Hovde Bragnes, Svanaug Skorpe, Turid Thune, Kathrine Aglen Seeberg, Brigitte Michelsen, Ingrid Marianne Blomgren, Eldri Kveine Strand, Pawel Mielnik, Roald Torp, Cato Mørk, Tore K. Kvien, Jørgen Jahnsen, Nils Bolstad, Espen A. Haavardsholm
Cite DOI
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
Importance: Proactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on scheduled monitoring of serum …
Silje Watterdal Syversen, Guro Løvik Goll, Kristin Kaasen Jørgensen, Øystein Sandanger, Joseph Sexton, Inge Christoffer Olsen, Johanna Elin Gehin, David John Warren, Marthe Kirkesæther Brun, Rolf Anton Klaasen, Lars Normann Karlsen, Geir Noraberg, Camilla Zettel, Maud-Kristine Aga Ljoså, Anne Julsrud Haugen, Rune Johan Njålla, Trude Jannecke Bruun, Kathrine Aglen Seeberg, Brigitte Michelsen, Eldri Kveine Strand, Svanaug Skorpe, Ingrid Marianne Blomgren, Yngvill Hovde Bragnes, Christian Kvikne Dotterud, Turid Thune, Carl Magnus Ystrøm, Roald Torp, Pawel Mielnik, Cato Mørk, Tore K. Kvien, Jørgen Jahnsen, Nils Bolstad, Espen A. Haavardsholm
Cite DOI
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
BACKGROUND: The NOR-SWITCH main and extension trials demonstrated that switching from originator to biosimilar infliximab (CT-P13) is …
Kristin K. Jørgensen, Guro L. Goll, Joe Sexton, Nils Bolstad, Inge C. Olsen, Øivind Asak, Ingrid P. Berset, Ingrid M. Blomgren, Katrine Dvergsnes, Jon Florholmen, Svein O. Frigstad, Magne Henriksen, Jon Hagfors, Gert Huppertz-Hauss, Espen A. Haavardsholm, Rolf A. Klaasen, Bjørn Moum, Geir Noraberg, Ulf Prestegård, Jan H. Rydning, Liv Sagatun, Kathrine A. Seeberg, Roald Torp, Cecilia Vold, David J. Warren, Carl M. Ystrøm, Knut E. A. Lundin, Tore Kvien, Jørgen Jahnsen
Cite DOI
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
BACKGROUND: TNF inhibitors have improved treatment of Crohn’s disease, ulcerative colitis, spondyloarthritis, rheumatoid …
Kristin K. Jørgensen, Inge C. Olsen, Guro L. Goll, Merete Lorentzen, Nils Bolstad, Espen A. Haavardsholm, Knut E. A. Lundin, Cato Mørk, Jørgen Jahnsen, Tore K. Kvien, NOR-SWITCH study group
Cite DOI